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CliBACKGROUND Bioprosthetic aortic valve degeneration is increasingly common, often unheralded, and can have
catastrophic consequences.
OBJECTIVES The authors sought to assess whether 18F-ﬂuoride positron emission tomography (PET)-computed
tomography (CT) can detect bioprosthetic aortic valve degeneration and predict valve dysfunction.
METHODS Explanted degenerate bioprosthetic valves were examined ex vivo. Patients with bioprosthetic aortic valves
were recruited into 2 cohorts with and without prosthetic valve dysfunction and underwent in vivo contrast-enhanced CT
angiography, 18F-ﬂuoride PET, and serial echocardiography during 2 years of follow-up.
RESULTS All ex vivo, degenerate bioprosthetic valves displayed 18F-ﬂuoride PET uptake that colocalized with tissue
degeneration on histology. In 71 patients without known bioprosthesis dysfunction, 14 had abnormal leaﬂet pathology on
CT, and 24 demonstrated 18F-ﬂuoride PET uptake (target-to-background ratio 1.55 [interquartile range (IQR): 1.44 to
1.88]). Patients with increased 18F-ﬂuoride uptake exhibited more rapid deterioration in valve function compared with
those without (annualized change in peak transvalvular velocity 0.30 [IQR: 0.13 to 0.61] vs. 0.01 [IQR: 0.05 to 0.16]
ms1/year; p < 0.001). Indeed 18F-ﬂuoride uptake correlated with deterioration in all the conventional echocardiographic
measures of valve function assessed (e.g., change in peak velocity, r ¼ 0.72; p < 0.001). Each of the 10 patients who
developed new overt bioprosthesis dysfunction during follow-up had evidence of 18F-ﬂuoride uptake at baseline (target-
to-background ratio 1.89 [IQR: 1.46 to 2.59]). On multivariable analysis, 18F-ﬂuoride uptake was the only independent
predictor of future bioprosthetic dysfunction.
CONCLUSIONS 18F-ﬂuoride PET-CT identiﬁes subclinical bioprosthetic valve degeneration, providing powerful
prediction of subsequent valvular dysfunction and highlighting patients at risk of valve failure. This technique holds major
promise in the diagnosis of valvular degeneration and the surveillance of patients with bioprosthetic valves. (18F-Fluoride
Assessment of Aortic Bioprosthesis Durability and Outcome [18F-FAABULOUS]; NCT02304276) (J Am Coll Cardiol
2019;73:1107–19) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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1108T he implantation of bioprostheticheart valves is increasing rapidlydue to patient preference, the
increasing prevalence of valve disease in an
aging population, and the emergence of
transcatheter aortic valve implantation
(1–4). In the United States, 90,000 surgical
aortic valve replacements are performedannually, with over three-quarters incorporating
bioprosthetic valves (3). In addition, >80,000 trans-
catheter aortic valve implantation procedures have
been performed since U.S. Food and Drug Administra-
tion approval in 2011 (4). Given the ﬁnite lifespan of
these valves and the rapid expansion of the popula-
tion of patients requiring regular surveillance,
bioprosthetic valve degeneration will become a major
cause of cardiovascular morbidity and health care
burden over the coming decades.SEE PAGE 1120The pathophysiology of bioprosthetic valve
degeneration is poorly understood. Although calciﬁ-
cation appears to contribute to both progressive valve
narrowing and leaﬂet tears (5–7), noninvasive
methods for detecting this process have been lacking,
and the triggers of valve degeneration and calciﬁca-
tion are unknown. Current standard of care relies on
serial echocardiography and clinical assessment
aimed at detecting the valve dysfunction that occurs
only toward the end stages of the degeneration
process. Unfortunately, many patients present in
extremis with unheralded valve failure due to rapid-
onset valvular obstruction or regurgitation, with
repeat operation a high-risk undertaking. Indeed,
emergency repeat aortic valve replacement surgery is
associated with a mortality of 22.6% compared with
1.4% for elective repeat surgery (8). Detection of
bioprosthetic valve degeneration is therefore highly
desirable, allowing at-risk patients to be identiﬁed
early, offered close tailored monitoring, and opti-
mized timing of repeat elective intervention, thereby
avoiding potentially catastrophic valve failure.
18F-ﬂuoride positron emission tomography (PET)
has recently been used to image tissue calciﬁcation
activity in a range of cardiovascular diseases (9–12).
18F-ﬂuoride preferentially binds to areas ofa Wellcome Trust Senior Investigator Award (WT103782AIA). Dr.
020; and is the recipient of the Sir Jules Thorn Award for Biomed
pport from Seimens Healthineers; has been a consultant for Imbio
Dr. Leipsic’s institution has served as an institutional core lab fo
consultant for and holds stock options in Circle CVI and HeartFlo
s relevant to the contents of this paper to disclose.
received September 12, 2018; revised manuscript received Novedeveloping microcalciﬁcation indicative of tissue
degeneration (13) that precede the macrocalciﬁcation
detectable by computed tomography (CT) (14,15).
Given that calciﬁcation is one of the key pathological
processes underlying bioprosthetic valve degenera-
tion, we hypothesized that increased 18F-ﬂuoride
uptake would identify prosthetic valve degeneration
and predict subsequent deterioration in bioprosthetic
valve function.
METHODS
EX VIVO ASSESSMENT OF DEGENERATED
BIOPROSTHETIC AORTIC VALVES. Explanted degen-
erated aortic valve bioprostheses were obtained with
written consent from patients undergoing repeat sur-
gical aortic valve replacement for bioprosthetic valve
failure. Valves were weighed, photographed, and their
macroscopic features documented. Ex vivo micro–
PET-CT was performed with a nano–PET-CT scanner
(Mediso, Budapest, Hungary) and x-ray microtomo-
graph (Bruker, Kontich, Belgium) before undergoing
histological evaluation (Online Appendix).
CLINICAL STUDY DESIGN AND POPULATION.
Patients over 40years of agewhohadundergoneprevious
surgical aortic valve replacement using a bioprosthetic
valve were prospectively recruited into a single-center
cohort study according to deﬁned inclusion and exclu-
sion criteria (Online Figure 1). Participants were recruited
if they were under routine clinical review and had: 1)
known evidence of bioprosthetic valve failure on echo-
cardiography and had been referred for repeat aortic
valve intervention (16,17); or 2) no known evidence of
valve dysfunction or degeneration. Written informed
consent was obtained from all participants. The study
(NCT02304276) was conducted in accordance with the
Declaration of Helsinki and was approved by an NHS
Scotland Research Ethics Committee (14/SS/1049) and the
Administration of Radioactive Substances Advisory
Committee.
STUDY ASSESSMENTS AND DATA COLLECTION. All
participants underwent baseline clinical assessment
including Doppler and 2-dimensional echocardiog-
raphy, noncontrast CT calcium scoring, contrast-
enhanced CT angiography, and in vivo 18F-ﬂuorideDweck is supported by the British Heart Foundation
ical Research 2015 JTA/15. Dr. van Beek has received
, Aidence NV, InHealth, and Mentholatum; and owns
r Edwards Lifesciences, Abbott, and Medtronic; and
w. All other authors have reported that they have no
mber 21, 2018, accepted December 2, 2018.
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were invited to return annually for 2 years for repeat
clinical assessments and echocardiography to assess
changes in bioprosthesis performance. Deﬁnitions of
bioprosthetic degeneration and dysfunction vary,
but in this study, we used deﬁnitions from both
contemporary international guideline criteria (16,17)
and a recent expert consensus statement (18)
(Online Appendix). Bioprosthetic valve failure was
deﬁned as the development of severe hemodynamic
valve dysfunction combined with patient symptoms,
the need for redo valve intervention, or valve-
related death (19). Patients were followed up for
the development of valve failure beyond the 2-year
timeframe using electronic patient record data.
PET AND CT IMAGE ANALYSIS. Fused PET and
contrast-enhanced CT images were reconstructed in
diastole, coregistered and reoriented to provide en
face images of the bioprosthetic valve with corre-
sponding long-axis views (Online Figure 2). Images
were analyzed by 2 experienced PET-CT observers
(T.R.G.C. and M.R.D.). Using pre-speciﬁed criteria,
CT scans were adjudicated to be abnormal if there
was pannus (circumferential low-attenuation
[noncalciﬁc] material with radial thickness $2 mm
and encroachment on the valve cusps) (16,20), non-
calciﬁc leaﬂet thickening (focal areas of low attenua-
tion [30 to 200 Hounsﬁeld Units (HU)] cusp
thickening $2 mm visualized in at least 2 planes)
(20,21), or leaﬂet calciﬁcation (calcium >500 HU
localized to valve cusp in #2 planes) (22). Leaﬂet
calciﬁcation was further subdivided into spotty
calciﬁcation if maximum diameter was <3 mm and
large calciﬁcation if maximum diameter was $3 mm
(23). 18F-ﬂuoride uptake was quantiﬁed primarily
using the most-diseased-segment mean target-to-
background ratio (TBR) method in keeping with
prior studies of the native valve, although other
measures were also reported (24). PET scans were
adjudicated to be abnormal if increased 18F-ﬂuoride
uptake (threshold TBR >1.3) (11) was observed origi-
nating from the valve cusps on both en face and long-
axis views (Online Appendix).
STATISTICS AND DATA ANALYSIS. Baseline charac-
teristics are reported as number (percentages) for
categorical variables and mean  SD or median
(interquartile range) for continuous variables
depending on whether variables were normally
distributed. Categorical data were compared using
chi-square or Fisher exact tests. Continuous variables
were log-transformed [logN(xþ1) for positive values
and logN(xþ1) for negative values] where not
normally distributed. The point-biserial correlationcoefﬁcient was used to measure the strength and di-
rection of the association between 1 dichotomous
variable and 1 continuous variable. One-way analysis
of variance was used to compare continuous data
across multiple factors, with post hoc analysis using
the Bonferroni test where appropriate. The Student’s
t-test or Mann-Whitney U test were used to compare
continuous outcomes between 2 independent groups
depending on whether they were normally distrib-
uted. The Student’s t-test or Wilcoxon signed rank
test were used to compare paired variables. Two-
tailed Pearson’s correlation analysis was performed
to investigate the relationship between 18F-ﬂuoride
uptake and echocardiographic measures of valve
function. Multivariable analysis was performed to
assess the predictors of deterioration in bioprosthetic
valve dysfunction (annualized change in peak veloc-
ity after 2 years). Statistical analysis was undertaken
using IBM SPSS Statistics version 23 software (IBM,
Armonk, New York), and signiﬁcance was taken at the
2-sided 5% level (p < 0.05).
RESULTS
EXPLANTED DEGENERATE BIOPROSTHETIC AORTIC
VALVES. Fifteen failed explanted bioprosthetic aortic
valves were obtained (Online Appendix) for ex vivo
investigation. Micro-CT detected leaﬂet calciﬁcation
in 13 valves, which was conﬁrmed on histology. By
contrast, all 15 valves demonstrated 18F-ﬂuoride
leaﬂet uptake that correlated with a range of histo-
logical markers of bioprosthetic tissue degeneration.
In particular, 18F-ﬂuoride activity detected both
micro- and macrocalciﬁc deposits within the valve
leaﬂets that colocalized predominantly with regions
of pannus (ﬁbrous thickening) and thrombus forma-
tion on histology. However, 18F-ﬂuoride uptake was
additionally observed in the absence of calciﬁcation
on histology at sites of leaﬂet thickening, ﬂuid insu-
dation, and disrupted collagen architecture (Figure 1).
CLINICAL COHORT STUDY POPULATION. Eighty
participants were recruited to the clinical cohort
study and underwent in vivo PET-CT imaging,
although 2 patients were unable to complete the
baseline scan (claustrophobia) and were excluded.
The remaining 78 patients were 75  7 years of age,
with a range of bioprosthetic valve models (Online
Tables 2 and 3), a high prevalence of coronary artery
disease, and associated risk factors (Table 1).
PATIENTS WITH SUSPECTED BIOPROSTHETIC
VALVE FAILURE. Seven participants were recruited
to the cohort with suspected bioprosthetic valve
failure. One subject proceeded to repeat surgical
aortic valve replacement, 5 underwent valve-in-valve
FIGURE 1 Ex Vivo Degenerated Bioprosthetic Aortic Valves: Macroscopic Appearances, Micro-CT, Micro-PET, and Histology
(Row A) Macroscopic visual appearances of failed and explanted bioprosthetic valves. (Row B) CT en face images of the valves. (Row C) PET en face images
demonstrating increased 18F-ﬂuoride uptake in all valves. (Row D) Histology staining of sections taken from valve leaﬂet as indicated, with von Kossa (top row, calcium
appears black), Movat Pentachrome (bottom row, valves 1 and 4), and hematoxylin and eosin (bottom row, valves 2 and 3) stains. All 4 degenerate bioprostheses
demonstrate increased 18F-ﬂuoride uptake in the valve leaﬂets. In valve 1, this uptake corresponds to gross leaﬂet calciﬁcation observed macroscopically and on CT
images with conﬁrmation on histology (extensive black staining). In valve 2, increased 18F-ﬂuoride uptake is observed in association with ﬁbrotic leaﬂet thickening and
pannus (red arrows) with associated calciﬁcation (black arrows) observed macroscopically and on CT with conﬁrmation on histology. In valve 3, increased 18F-ﬂuoride
uptake is observed at the site of valve leaﬂet thrombus (red arrow) observed macroscopically at the base of leaﬂet 1, with conﬁrmation of thrombus (red arrow) and
colocalized calciﬁcation (black arrow) on histology. In valve 4, extensive 18F-ﬂuoride uptake is observed in the absence of calciﬁcation on CT and histology but instead
in areas of leaﬂet thickening, marked ﬂuid insudation, and disrupted collagen architecture. CT ¼ computed tomography; PET ¼ positron emission tomography.
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1110transcatheter valve implantation, and 1 subject was
deemed to have severe patient–prosthesis mismatch
according to guideline criteria and therefore not
considered to have valve failure (16,17). All 6
subjects with conﬁrmed bioprosthetic valve failuredemonstrated abnormalities on both CT and
18F-ﬂuoride PET studies (Figure 2). CT revealed evi-
dence of leaﬂet calciﬁcation in all patients (spotty
calciﬁcation n ¼ 3, large calciﬁcation n ¼ 3) and less
commonly noncalciﬁc leaﬂet thickening (n ¼ 2),
TABLE 1 Baseline Characteristics of the Clinical Study Population Undergoing in Vivo PET and CT Imaging
Patients With
Valve Failure
Patients Without Known Valve Degeneration
All 1 Month 2 Year 5 Year 10 Year
Clinical
Subjects 6 71 9 22 20 20
Female 2 (33.3) 38 (46.5) 5 (55.6) 8 (36.4) 10 (50.0) 10 (50.0)
Age, yrs 81.3  3.2 73.9  7.0 73.4  9.0 73.0  5.4 72.7  5.1 76.4  8.9
Body mass index, kg/m2 27.5  4.5 26.9  5.6 27.8  4.7 27.7  4.8 27.8  5.1 24.8  6.8
Systolic blood pressure, mm Hg 144.8  18.0 153.8  21.9 152.4  21.2 149.8  22.1 158.1  15.2 154.5  27.8
Diastolic blood pressure, mm Hg 58.0  8.4 79.0  11.0 82.0  11.4 81.3  12.0 78.6  7.4 75.4  12.6
Heart rate, beats/min 72.2  17.0 71.2  11.8 79.8  10.0 69.7  11.6 73.3  13.4 66.6  8.9
Medical history
Hypertension 4 (66.7) 50 (70.4) 8 (88.9) 16 (72.7) 14 (70.0) 12 (60.0)
Coronary artery disease 4 (66.7) 29 (40.9) 5 (55.6) 7 (31.8) 6 (30.0) 11 (55.0)
Coronary bypass surgery 3 (50.0) 23 (32.4) 2 (22.2) 7 (31.8) 5 (25.0) 9 (45.0)
Diabetes 1 (16.7) 4 (5.6) 0 (0.0) 0 (0.0) 2 (10.0) 2 (10.0)
Hypercholesterolemia 5 (83.3) 55 (77.5) 8 (88.9) 18 (81.8) 13 (65.0) 16 (80.0)
Current smoker 0 (0.0) 8 (11.4) 0 (0.0) 1 (4.6) 3 (15.0) 4 (20.0)
Ex-smoker 3 (50.0) 29 (40.8) 4 (44.4) 10 (45.5) 7 (35.0) 8 (40.0)
Medication
Aspirin 4 (66.7) 51 (71.8) 7 (77.8) 18 (81.8) 12 (60.0) 14 (70.0)
Clopidogrel 1 (16.7) 9 (12.7) 1 (11.1) 2 (9.1) 4 (20.0) 2 (10.0)
Warfarin 2 (33.3) 4 (5.6) 0 (0.0) 1 (4.5) 3 (15.0) 0 (0.0)
Other anticoagulant 0 (0.0) 2 (2.8) 0 (0.0) 0 (0.0) 1 (5.0) 1 (5.0)
ACEi or ARB 0 (0.0) 39 (54.9) 6 (66.7) 12 (54.5) 10 (50.0) 11 (55.0)
Beta-blocker 2 (33.3) 32 (45.1) 4 (44.4) 13 (59.1) 7 (35.0) 8 (40.0)
Statin 4 (66.7) 50 (70.4) 6 (66.7) 15 (68.2) 14 (70.0) 14 (70.0)
Biochemistry
Creatinine, mmol/l 102.2  37.2 84.5  23.4 90.3  36.4 80.9  17.8 89.1  19.8 81.3  25.4
eGFR, ml/min/1.73 m2 48.5  13.0 58  7.5 53.4  11.8 59.8  3.2 57.1  6.8 59.2  8.5
Electrocardiogram
Sinus rhythm 4 (66.7) 64 (91.4) 9 (100.0) 20 (95.2) 18 (90.0) 17 (85.0)
Paced rhythm 0 (0.0) 4 (5.7) 0 (0.0) 0 (0.0) 1 (5.0) 3 (15.0)
Atrial ﬁbrillation 2 (33.3) 2 (2.9) 0 (0.0) 1 (4.8) 1 (5.0) 0 (0.0)
LV hypertrophy 3 (50.0) 22 (32.4) 4 (44.4) 7 (33.3) 9 (45.0) 2 (11.1)
Strain pattern 3 (50.0) 14 (20.6) 4 (44.4) 2 (9.5) 6 (30.0) 2 (11.1)
Baseline echocardiography
LV systolic dysfunction 4 (66.7) 11 (15.5) 1 (11.1) 3 (13.6) 4 (20.0) 3 (15.0)
Peak valve velocity, m/s 3.19 (2.84–4.47) 2.73 (2.38–3.07) 2.44 (2.27–2.75) 2.68 (2.28–2.82) 2.93 (2.55–3.40) 2.85 (2.36–3.13)
Mean valve gradient, mm Hg 20.6 (14.0–39.5) 15.0 (11.3–19.3) 13.0 (10.0–15.0) 13.9 (10.2–17.8) 18.5 (13.1–23.8) 17.2 (11.1–20.8)
Effective oriﬁce area, cm2 0.52 (0.52–0.52) 1.13 (0.94–1.46) 1.33 (0.95–1.60) 1.14 (0.95–1.46) 1.03 (0.92–1.31) 1.20 (0.86–1.49)
Dimensionless velocity index 0.29 (0.20–0.42) 0.39 (0.33–0.44) 0.47 (0.38–0.51) 0.40 (0.36–0.43) 0.35 (0.31–0.40) 0.38 (0.31–0.46)
Prosthetic regurgitation, $ moderate 5 (83.3) 2 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (10.0)
Acceleration time, ms * 80.3 (75.2–87.4) 87.0 (74.0–93.0) 80.0 (75.0–85.0) 79.0 (75.0–86.0) 85.0 (76.7–94.0)
Acceleration time/LV ejection time * 0.25 (0.24–0.28) 0.29 (0.25–0.31) 0.25 (0.24–0.27) 0.25 (0.23–0.27) 0.25 (0.22–0.28)
Computed tomography
Abnormal ﬁndings 6 (100.0) 14 (19.7) 0 (0.0) 3 (13.6) 4 (20.0) 7 (30.0)
Spotty calciﬁcation 3 (50.0) 5 (7.0) 0 (0.0) 1 (4.5) 1 (5.0) 3 (15.0)
Large calciﬁcation 3 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Noncalciﬁc leaﬂet thickening 2 (33.3) 5 (7.0) 0 (0.0) 1 (4.5) 3 (15.0) 1 (5.0)
Pannus 1 (16.7) 7 (9.9) 0 (0.0) 2 (9.1) 0 (0.0) 5 (25.0)
18F-ﬂuoride positron emission tomography
Leaﬂet uptake 6 (100.0) 24 (33.8) 1 (11.1) 6 (27.2) 8 (40.0) 9 (45.0)
SUV MDS max 4.66 (3.16–7.57) 1.73 (1.42–2.02) 1.89 (1.42–1.99) 1.50 (1.31–1.80) 1.94 (1.39–2.26) 1.73 (1.54–2.34)
SUV MDS mean 3.50 (2.64–5.90) 1.48 (1.27–1.84) 1.59 (1.29–1.82) 1.31 (1.14–1.57) 1.72 (1.21–2.05) 1.44 (1.32–2.04)
TBR MDS max 3.61 (2.37–5.82) 1.31 (1.18–1.70) 1.26 (1.17–1.35) 1.26 (1.12–1.47) 1.52 (1.17–1.82) 1.47 (1.24–2.12)
TBR MDS mean 2.91 (2.10–4.09) 1.12 (1.04–1.51) 1.07 (1.06–1.18) 1.11 (1.00–1.31) 1.38 (1.01–1.62) 1.15 (1.06–1.87)
Values are n, n (%), mean  SD, or median (interquartile range). *Incomplete data.
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blockade; CT ¼ computed tomography imaging; eGFR ¼ estimated glomerular ﬁltration rate; LV ¼ left ventricle; MDS ¼ most
diseased segment; PET ¼ positron emission tomography; SUV ¼ standardized uptake value; TBR ¼ target-to-background ratio.
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FIGURE 2 In Vivo 18F-ﬂuoride PET and CT Imaging of Patients With Bioprosthetic Aortic Valves
Baseline CT (left) and 18F-ﬂuoride PET (right) images from patients with bioprosthetic aortic valves. En face CT images of aortic bioprosthetic valves showing
spotty calciﬁcation and large calciﬁcation (top left), circumferential pannus (bottom left), and noncalciﬁc leaﬂet thickening suggestive of thrombus (top right)
(all abnormalities identiﬁed by red arrows). Hybrid en face PET-CT images in the same patients: increased bioprosthetic 18F-ﬂuoride activity (red/yellow areas) is
observed in each patient colocalizing with the CT abnormalities. 18F-ﬂuoride activity was also commonly observed remote from leaﬂet changes on CT (bottom right).
Target-to-background (TBR) values are annotated on the hybrid PET-CT images in white text. Abbreviations as in Figure 1.
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1112circumferential pannus (n ¼ 1), and distorted leaﬂet
morphology (n ¼ 1). Increased 18F-ﬂuoride PET leaﬂet
uptake was observed in the bioprosthetic valves of all
these patients, and TBR values were nearly 3 times
higher than in patients without known valvular
dysfunction (TBR 2.91 [interquartile range (IQR): 1.75 to
4.09] vs. 1.12 [IQR: 1.04 to 1.51]; p < 0.001). In the 1
patient with severe patient–prosthesis mismatch, there
was no CT abnormality or 18F-ﬂuoride uptake.PATIENTS WITHOUT KNOWN BIOPROSTHETIC
VALVE DYSFUNCTION. In the 71 patients without
known bioprosthetic valve dysfunction, surgical
aortic valve replacement had been conducted 1 month
(n ¼ 9), 2 years (n ¼ 22), 5 years (n ¼ 20), and >10
years (n ¼ 20) previously. The function of these
different-aged valves was generally within normal
limits at baseline (peak velocity 2.76  0.52 m/s, mean
gradient 16.4  7.0 mm Hg) (Table 1).
TABLE 2 Correlation Between Bioprosthetic 18F-ﬂuoride Uptake and Subsequent
Deterioration in Valve Function by Echocardiography
Annualized Change
SUV Mean
(LogN)
SUV Max
(LogN)
TBR Mean
(LogN)
TBR Max
(LogN)
Peak valve velocity, LogN r ¼ 0.58
p < 0.001*
r ¼ 0.62
p < 0.001*
r ¼ 0.72
p < 0.001*
r ¼ 0.72
p < 0.001*
Mean valve gradient, LogN r ¼ 0.42
p < 0.001*
r ¼ 0.45
p ¼ 0.001*
r ¼ 0.52
p < 0.001*
r ¼ 0.52
p < 0.001*
Effective oriﬁce area, cm2/yr r ¼ 0.45
p < 0.001*
r ¼ 0.52
p < 0.001*
r ¼ 0.57
p < 0.001*
r ¼ 0.60
p < 0.001*
Doppler velocity index r ¼ 0.46
p < 0.001*
r ¼ 0.51
p < 0.001*
r ¼ 0.59
p < 0.001*
r ¼ 0.60
p < 0.001*
In 71 volunteers with bioprosthetic aortic valves without known valve dysfunction, baseline 18F-ﬂuoride uptake
measured by positron emission tomography using any conventional method of quantiﬁcation (SUV or TBR) was
associated with subsequent deterioration in each echocardiographic measure of valve function. Note all values
are based upon the most-diseased-segment approach. The TBR mean values were used as the primary
comparison and are referred to elsewhere in the paper simply as the TBR abbreviation. *Statistically signiﬁcant.
Abbreviations as in Table 1.
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1113Contrast-enhanced CT images were not interpret-
able in 8 patients (11%) due to motion degradation and
metallic blooming artefact from the valve struts.
Fourteen subjects (19%) had 1 or more leaﬂet abnor-
malities on CT: spotty calciﬁcation (n ¼ 5), noncalciﬁc
leaﬂet thickening (n ¼ 5), and pannus (n ¼ 7) (Figure 2).
PET scans were interpretable in all patients.
Increased 18F-ﬂuoride uptake was more common than
abnormalities on CT and was seen in 24 patients
(34%) (TBR 1.55 [IQR: 1.44 to 1.88]) (Figure 2, Online
Figure 3). Similar to the ex vivo ﬁndings, increased
18F-ﬂuoride uptake colocalized with areas of spotty
calciﬁcation, noncalciﬁc leaﬂet thickening (sugges-
tive of thrombus), and pannus observed on the CT,
but was also observed remote from CT abnormalities
(Figure 2).
PREDICTION OF BIOPROSTHETIC VALVE DYSFUNCTION.
Sixty-seven of the patients without established valve
degeneration at baseline underwent repeat echocar-
diography at 2 years and demonstrated increased
peak velocities compared with baseline (2.87 [IQR:
2.52 to 3.13] m/s vs. 2.73 [IQR: 2.38 to 3.07] m/s;
p ¼ 0.002). There was no association between he-
modynamic progression and either the type or the age
of the bioprosthesis (Online Table 4).
The 14 patients with abnormal CT ﬁndings
appeared to demonstrate deterioration in bio-
prosthetic valve function after 2 years, but there was
no statistical difference in disease progression
compared with patients with a normal CT (change in
peak velocity: 0.25 [IQR: 0.06 to 0.57] m/s vs. 0.10
[IQR: 0.04 to 0.31] m/s; p ¼ 0.232).
By contrast, the 24 patients with increased
18F-ﬂuoride uptake at baseline demonstrated clear
evidence of deteriorating bioprosthesis function after
2 years, whereas patients without uptake displayed
no change in valve function (change in peak velocity:
0.30 [IQR: 0.13 to 0.61] vs. 0.01 [IQR: 0.05 to 0.16]
m/s/year; p < 0.001). Similarly, valves demonstrated
progressive hemodynamic deterioration during
follow-up on moving across tertiles of 18F-ﬂuoride
uptake (Online Figure 3). Moreover, baseline
18F-ﬂuoride uptake correlated strongly with all
echocardiographic measures of hemodynamic pro-
gression regardless of the method used to quantify
18F-ﬂuoride uptake (Table 2).
On the basis of international guideline criteria
(16,17), 10 patients developed new bioprosthetic valve
dysfunction during follow-up: 2 with valve regurgi-
tation, 6 with valve stenosis, and 2 with mixed
dysfunction. Median time from valve implantation to
their assessment in the study was 7.5 (5 to 10) years.
Of these patients, 5 had an abnormal baseline CT,
whereas all 10 patients had increased 18F-ﬂuorideuptake (TBR 1.89 [IQR: 1.46 to 2.59]), and this
included the 7 patients with the highest TBR values in
the cohort. Two proceeded to urgent valve reinter-
vention, and another died of valve failure. Using the
alternative criteria suggested by the recent interna-
tional consensus statement (18), 16 patients met the
deﬁnition of structural valve degeneration, 15 of
whom demonstrated increased 18F-ﬂuoride uptake
(TBR 1.54 [IQR: 1.38 to 1.96] vs. 1.08 [IQR: 1.02 to 1.19];
p < 0.001). Seven patients fulﬁlled criteria for stage 2
or 3 structural valve degeneration, signifying the
development of valve dysfunction, and they all
exhibited increased baseline 18F-ﬂuoride uptake
(TBR 1.89 [IQR: 1.47 to 3.15]) (Figure 3). Moreover,
18F-ﬂuoride activity increased in a stepwise fashion
across these progressive stages of structural degen-
eration (TBR no degeneration: 1.08 [IQR: 1.02 to 1.19],
stage 1: 1.48 [IQR: 1.34 to 1.64], stage 2: 1.72 [IQR: 1.42
to 1.94], stage 3: 4.23 [IQR: 3.15 to 5.36]; post hoc
linear trend p < 0.001) (Figure 3). Two patients
developed overt bioprosthetic valve failure during
2-year follow-up, and a further 2 patients developed
valve failure on subsequent follow-up, all demon-
strating high-intensity 18F-ﬂuoride uptake (TBR 2.57
[IQR: 1.96 to 3.70]) (19) (Figure 4).
On univariable analysis, the only predictors
of deterioration in bioprosthetic valve function
(annualized change in bioprosthetic valve peak ve-
locity) were current smoking habit (p ¼ 0.047) and
18F-ﬂuoride PET uptake, irrespective of whether the
latter was considered as a categorical or continuous
variable (both p < 0.001) (Online Table 4). On multi-
variable analysis incorporating age, sex, duration of
valve implantation, baseline peak prosthetic valve
velocity, and CT ﬁndings, 18F-ﬂuoride uptake
emerged as the only predictor of deterioration
in bioprosthetic valve function (unstandardized
FIGURE 3 Baseline 18F-ﬂuoride PET Uptake Predicts Subsequent Deterioration in Bioprosthetic Valve Function After 2 Years
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(A) A strong correlation was observed between baseline 18F-ﬂuoride uptake in the bioprosthetic valves (TBR) and subsequent progression in bioprosthetic valve peak
velocity (log transformation applied; r ¼ 0.72; p < 0.001). Orange dots signify patients who developed new bioprosthetic valve regurgitation during follow-up.
(B) 18F-ﬂuoride uptake (dashed orange line represents threshold for increased 18F-ﬂuoride uptake; TBR 1.3) in patients with different stages of structural valve
degeneration after 2-year follow-up (stage 0: no signiﬁcant change from post-implantation [n ¼ 54]; stage 1: morphological abnormalities without signiﬁcant
hemodynamic changes [n ¼ 9]; stage 2: new moderate stenosis and/or regurgitation [n ¼ 5]; stage 3: new severe stenosis and/or severe regurgitation [n ¼ 2]) (18)
demonstrating incrementally higher uptake values with increasing severity of structural valve degeneration. (C and D) Forest plots of unstandardized coefﬁcients
(95% conﬁdence intervals) from a multivariable linear regression analysis predicting change in bioprosthetic valve function (annualized change in peak velocity) during
follow-up. When examining all relevant baseline characteristics, 18F-ﬂuoride uptake was the only independent predictor of hemodynamic deterioration in valve
function when used both as a dichotomous variable (PETþ, TBR >1.3) (C) and as a continuous variable (TBR) (D). CI ¼ conﬁdence interval; other abbreviations as in
Figures 1 and 2.
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1114coefﬁcient 0.79 [95% conﬁdence interval: 0.62 to
0.96]; p < 0.001) (Figure 3, Online Table 5).
Irrespective of the deﬁnition used (16–18), similar
results were observed when the development of bio-
prosthetic valve dysfunction was considered as a
categorical variable, with baseline 18F-ﬂuoride uptake
emerging each time as an independent predictor on
multivariable analyses (international guideline
criteria [16,17]: unstandardized coefﬁcient 7.57[standard error 2.66]; p ¼ 0.004); expert consensus
statement [18]: unstandardized coefﬁcient 6.81
[standard error 2.92]; p ¼ 0.02) (Online Table 6).
DISCUSSION
In this multimodality prospective imaging study, we
have identiﬁed 18F-ﬂuoride PET-CT as the ﬁrst
noninvasive technique capable of detecting early
FIGURE 4 Case Illustrations: Baseline 18F-ﬂuoride PET and CT Predict Imminent Failure of Bioprosthetic Function
Cases 1 to 4 illustrate the utility of 18F-ﬂuoride PET and CT in the prediction of deteriorating valve performance. None of the patients had known bioprosthetic
degeneration at baseline. En face contrast-enhanced CT images (top row) demonstrate noncalciﬁc leaﬂet thickening in case 1, but no clear structural CT changes in the
remaining cases. Hybrid 18F-ﬂuoride PET-CT images (middle row) demonstrate high-intensity 18F-ﬂuoride activity in all the valves (TBR values in white). Doppler
echocardiographic assessments of bioprosthetic valve function after follow-up (bottom row). In each case, new valve dysfunction has developed with progression to
severe obstruction in cases 1, 2, and 3 and new moderate/severe eccentric regurgitation in case 4 (pressure half time 316 ms with holodiastolic ﬂow reversal in aorta).
Patient #1 died from valve-related heart failure, Patient #2 required redo surgical valve replacement, Patient #3 remains under close surveillance, and Patient #4 is
undergoing work-up for redo surgery.
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1115bioprosthetic valve degeneration and of predicting
future valve dysfunction (Central Illustration). We
provide extensive validation of the technique against
state-of-the-art ex vivo imaging and histology. This
consistently demonstrated increased 18F-ﬂuoride
uptake in each of the failed bioprosthetic aortic
valves examined, with PET activity colocalizing to
areas of calciﬁcation, pannus, thrombus, and dis-
rupted tissue architecture on histology. When applied
to patients in the clinical setting, 18F-ﬂuoride PET
identiﬁed early valve degeneration beyond the reso-
lution of conventional assessments and predicted the
development of new valvular dysfunction and overtvalve failure within the 2-year follow-up period.
Indeed, 18F-ﬂuoride uptake was an independent pre-
dictor of deteriorating bioprosthetic valve perfor-
mance, outperforming all other variables, including
valve type and age, and echocardiographic and CT
ﬁndings. 18F-ﬂuoride PET-CT, therefore, provides a
readily applicable measure of valve degeneration
with the potential to transform how we monitor and
treat the expanding population of patients living with
bioprosthetic valves.
Our study has several major strengths. This is
a comprehensive multimodal imaging study using
ultrasound, CT, and PET in patients with
CENTRAL ILLUSTRATION Pathogenesis of Bioprosthetic Valve Degeneration and Utility of 18F-Fluoride Positron
Emission Tomography
Cartlidge, T.R.G. et al. J Am Coll Cardiol. 2019;73(10):1107–19.
(Left column) Potential mechanisms of initial valve injury include leaﬂet thrombosis, ﬁbrosis, and matrix degradation with expansion of the central proteoglycan layer,
ﬂuid insudation, and disruption of normal collagen architecture. (Middle column) Each appears to lead to bioprosthetic valve calciﬁcation as the ﬁnal common
pathway for valve degeneration that can be detected with 18F-ﬂuoride PET imaging. (Right column) Baseline 18F-ﬂuoride uptake correlates strongly with subsequent
deterioration in valve function during follow-up (annualized change in peak transvalvular velocity: r ¼ 0.72; p < 0.001) (top). Two examples demonstrate high-
intensity 18F-ﬂuoride leaﬂet uptake at baseline in valves without previous evidence of degeneration. After follow-up, both bioprosthetic valves developed clear
evidence of dysfunction: one with severe stenosis, and the other, regurgitation. PET ¼ positron emission tomography.
Cartlidge et al. J A C C V O L . 7 3 , N O . 1 0 , 2 0 1 9
Bioprosthetic Aortic Valve Degeneration M A R C H 1 9 , 2 0 1 9 : 1 1 0 7 – 1 9
1116bioprosthetic aortic valves of varying implant ages.
Uniquely, we have been able to correlate imaging
ﬁndings with state-of-the-art ex vivo imaging and
histological characterization of explanted valves,
enabling us to validate our imaging technique and
provide novel insights into the pathogenesis of
bioprosthetic valve degeneration. Moreover, our
systematic prospective study design has allowed us to
conﬁrm the utility of baseline 18F-ﬂuoride PET in
identifying patients at risk of developing future bio-
prosthetic dysfunction and overt valve failure.
A CLINICAL CHALLENGE. Although bioprosthetic
valves offer important advantages over mechanical
valves, they have only limited durability (25,26).
Indeed, bioprosthetic valve degeneration has become
a major clinical issue with the growing rate ofbioprosthetic valve implantation and improved long-
term patient survival. Although international guide-
lines recommend serial echocardiography for the
detection of bioprosthetic degeneration (16,17), visu-
alization of the valve is often poor due to acoustic
artefacts from the prosthesis, limiting its sensitivity.
This means that valve degeneration is frequently
well advanced before clinically overt valve dysfunc-
tion is apparent. Moreover, valve obstruction often
evolves rapidly, whereas the catastrophic develop-
ment of valvular regurgitation due to leaﬂet tears
is frequently unheralded and unpredictable. Novel
techniques capable of detecting the earlier stages of
valve degeneration and allowing personalized and
better planned management strategies for patients
with bioprosthetic valves are therefore highly
desirable.
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1117INSIGHTS INTO THE MECHANISM OF BIOPROSTHETIC
VALVE DEGENERATION. We and others have used
18F-ﬂuoride PET to assess cardiovascular calciﬁcation
activity and tissue degeneration in a range of condi-
tions including coronary heart disease, stroke,
abdominal aortic aneurysms, and aortic stenosis
(9–12). We now extend these observations to bio-
prosthetic valves and conﬁrm that 18F-ﬂuoride local-
izes to regions of developing leaﬂet calciﬁcation on
histology and high-resolution micro–PET-CT imaging.
Calciﬁcation is believed to be the ﬁnal common
response to bioprosthetic valve injury and a major
driver toward valve dysfunction, causing both
progressive cusp stiffness and obstruction as well
as leaﬂet fragility and tears. In this study, all bio-
prosthetic valves with established degeneration and
valve failure demonstrated increased 18F-ﬂuoride
uptake. Moreover, in both our ex vivo and in vivo
studies, we observed a close spatial interaction of
calciﬁcation with both leaﬂet thrombosis and pannus,
suggesting these may be potential upstream triggers.
By contrast, a minority of bioprosthetic valves appear
to degenerate without any histological evidence of
calciﬁcation. In these cases, the remarkable histo-
logical features were gross leaﬂet thickening, ﬂuid
insudation, and disruption of normal collagen archi-
tecture. Interestingly, these valves also exhibited
high levels of 18F-ﬂuoride uptake. We hypothesize
that up-regulation of matrix metalloproteinases may
be implicated in the degradation of bioprosthetic
leaﬂet tissue and that these proteins have the po-
tential to bind 18F-ﬂuoride (27,28). Further investi-
gation of the mechanism of uptake is required.
Recent reports have described focal noncalciﬁc
leaﬂet thickening as a marker of thrombus formation
(20,29). Although these areas can cause acute valve
obstruction, more commonly, they do not result in
any immediate hemodynamic disturbance, leading
some to question their clinical relevance. In our
study, we also observed low-attenuation noncalciﬁc
leaﬂet thickening on CT, suggestive of non-
obstructive thrombus, that was associated with both
increased 18F-ﬂuoride activity and delayed deterio-
ration in valve performance over the following
2 years. Similar ﬁndings were observed in explanted
valves, where areas of thrombus colocalized with
calcium on Von Kossa staining and exhibited
increased 18F-ﬂuoride PET activity. This raises the
hypothesis that bioprosthetic valve thrombosis may
act as one potential trigger to valve degeneration
that might be prevented with prompt detection and
anticoagulation. Interestingly, recent observational
data have suggested that bioprosthetic durabilitymay be enhanced by concomitant anticoagulation
therapy (30).
CLINICAL IMPLICATIONS. Our ﬁndings have several
major implications for clinical practice. First, in
addition to micro- and macrocalciﬁcation, 18F-ﬂuo-
ride PET-CT can identify a range of degenerative
processes including ﬁbrosis, thrombosis, and leaﬂet
degradation with disrupted collagen architecture and
ﬂuid insudation. This has provided important in-
sights into the pathogenesis of bioprosthetic valve
failure and highlights potential targets for novel
therapies aimed at improving valve durability. Sec-
ond, 18F-ﬂuoride PET can detect and quantify the
early stages of valvular degeneration and identify
patients otherwise thought to have normal valves but
who are in fact at high risk of subsequent valve fail-
ure. Given the high mortality associated with emer-
gency repeat valve replacement (8), these patients are
likely to beneﬁt from both close tailored surveillance
and early elective intervention before the onset of
abrupt valve failure. Conversely, patients without
PET uptake, who here demonstrated very stable valve
function during follow-up, could undergo less inten-
sive surveillance. Our data suggest that 5 years post-
implantation may be an appropriate stage at which
to offer a PET-CT scan and guide follow-up, with
further studies needed. Third, 18F-ﬂuoride PET-CT
appears of value in determining the presence of
valvular degeneration in cases where the diagnosis
and clinical management is uncertain, for example in
patients with suspected patient–prosthesis mismatch.
Finally, 18F-ﬂuoride PET-CT provides a readily appli-
cable measure of valve durability that may prove
useful in assessing novel prosthetic designs such as
transcatheter valves before these are extended into
younger and healthier patient populations.
STUDY LIMITATIONS. It was initially envisaged that
serial CT calcium scoring of bioprosthetic aortic
valves would also provide a marker of valve degen-
eration. However, in our hands, we observed major
artefact related to motion and the valve frame that
precluded accurate analysis of CT calcium scores.
Leaﬂet pathology was instead more successfully
identiﬁed by contrast-enhanced CT, where superior
anatomic detail allowed differentiation between
pannus ingrowth, thrombosis, or calciﬁcation,
although a minority of scans still could not be accu-
rately adjudicated. Alongside the robust information
provided by 18F-ﬂuoride PET this is an important
advantage of the hybrid PET/CT technique.
Although our study population is relatively large
compared with other cardiovascular PET studies,
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: 18F-ﬂuoride PET-CT imag-
ing can detect early bioprosthetic valve degeneration
and predict subsequent valve dysfunction, identifying
patients at high risk of earlier valve failure.
TRANSLATIONAL OUTLOOK: Pragmatic studies
are needed to deﬁne the role of 18F-ﬂuoride PET-CT
imaging in protocols for the surveillance of patients
with bioprosthetic valves.
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1118external validation in a larger study population with
longer follow-up would be welcome. Future studies
may wish to investigate 18F-ﬂuoride activity in novel
bioprostheses, in particular aortic and mitral trans-
catheter valves, as well as assessing whether the
bioprosthetic 18F-ﬂuoride signal is modiﬁable
with adjuvant therapies, such as anticoagulation in
patients with associated thrombus or drugs that
modify calcium metabolism (e.g., bisphosphonates,
denosumab).
CONCLUSIONS
18F-ﬂuoride PET-CT detects early bioprosthetic valve
degeneration, providing powerful prediction of sub-
sequent deterioration in valve performance and
highlighting patients at imminent risk of valve fail-
ure. This novel imaging approach has the potential to
transform our understanding of bioprosthetic valve
failure and the way in which we monitor and treat
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APPENDIX For expanded Methods and
Results sections as well as supplemental ﬁgures
and tables, please see the online version of this
paper.
